One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Werewolf Therapeutics, Inc.
HOWL · NCM · Healthcare · Biotechnology
Current price
$0.97
52-week range
$0.27 - $1.20
Market cap
$47.14M
Balance sheet
Healthy
-11.50x Concerning
Net cash $21.99M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Werewolf Therapeutics, Inc.
Werewolf Therapeutics is a company trying to create new medicines that use your own body's defense system to fight diseases like cancer. They don't sell anything yet because these are still in the testing stages, so their money mainly comes from investors funding their research. This matters because if their experiments work, they could bring important new treatments to patients.
How the company got here
Werewolf Therapeutics, Inc. was founded in 2017 with a mission to harness the power of the body's own immune system to fight diseases like cancer. The company's journey is centered around its innovative PREDATOR platform, a technology designed to create "smart" drug molecules. These molecules are engineered to activate the immune system only when and where they are needed, aiming to overcome the challenges of traditional immune therapies that can sometimes cause unwanted side effects by being too broadly active. This foundational technology is what shapes the company's current development pipeline.
What it actually does
Werewolf Therapeutics is a biopharmaceutical company focused on developing new medicines, primarily for cancer and other conditions where the immune system plays a key role. They don't sell any products directly to consumers yet; instead, they are in the research and development phase, creating potential new treatments. Their approach involves designing molecules that act like signals to the body's immune cells, telling them to attack diseased cells, such as cancer cells. Think of it like giving the immune system a highly specific set of instructions to find and eliminate threats without causing unnecessary collateral damage.
INDUKINE Molecules
This is the core of Werewolf's business, focusing on developing a class of drugs called INDUKINE molecules. These are engineered proteins designed to stimulate the body's immune system. The company has several INDUKINE candidates in development, each targeting different aspects of the immune response and different diseases. For example, WTX-124 and WTX-330 are designed to treat advanced or metastatic solid tumors, while WTX-921 is being explored for inflammatory bowel disease. These represent the company's primary efforts to create new therapies, and they are the main focus of the company's research and investment.
INDUCER T cell engagers
Another area of development for Werewolf Therapeutics involves INDUCER T cell engager molecules. These are a different type of therapeutic molecule designed to bring immune cells, specifically T cells, directly to cancer cells. The goal is to create a more targeted attack on the cancer. Their candidate WTX-1011, for instance, is designed to target STEAP 1 for prostate cancer. This segment of their work represents a distinct strategy within their broader goal of leveraging the immune system to fight disease, offering another potential avenue for future treatments.
What management is betting on now
Werewolf's management is primarily focused on advancing their pipeline of novel therapeutics through clinical trials. Their key strategy revolves around the successful development and potential approval of their INDUKINE and INDUCER molecules, such as WTX-124 and WTX-1011. The company is betting that their proprietary PREDATOR platform can consistently produce highly targeted and effective immune-stimulating therapies. Success in these clinical trials is crucial, as it could lead to new treatments for patients and significant value for the company.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-12.46M
FY2024 Q4
$-14.38M
FY2025 Q1
$-18.95M
FY2025 Q2
$-15.16M
FY2025 Q3
$-15.16M
FY2025 Q4
$-11.02M
Revenue
—
Net income
$3.67M
Diluted EPS
0.08
Operating cash flow
$6.63M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-13.53M
Diluted EPS
-0.28
Operating cash flow
$-10.60M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-8.38M
Diluted EPS
-0.17
Operating cash flow
$-11.02M
Free cash flow
$-11.02M
Fetching…
Sources
Revenue
—
Net income
$-16.37M
Diluted EPS
-0.36
Operating cash flow
$-15.16M
Free cash flow
$-15.16M
Fetching…
Sources
Revenue
—
Net income
$-17.98M
Diluted EPS
-0.40
Operating cash flow
$-15.16M
Free cash flow
$-15.16M
Fetching…
Sources
Revenue
—
Net income
$-18.09M
Diluted EPS
-0.40
Operating cash flow
$-18.95M
Free cash flow
$-18.95M
Fetching…
Sources
Revenue
—
Net income
$-20.40M
Diluted EPS
-0.43
Operating cash flow
$-14.25M
Free cash flow
$-14.38M
Fetching…
Sources
Revenue
—
Net income
$-16.67M
Diluted EPS
-0.38
Operating cash flow
$-12.46M
Free cash flow
$-12.46M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.97
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $22.0M - more cash than debt. Interest coverage -11.5x.
Net debt
$-21.99M
Interest coverage
-11.50x
Werewolf Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
HOWL
BASELINE
Werewolf Therapeutics, Inc.
Total debt $0.00 Interest coverage -11.50x This is the baseline the peer rows are being compared against.
Total debt $4.39M Interest coverage -4.30x Neither company has much profit cushion over interest right now.
Total debt $11.04M Interest coverage -62.95x Neither company has much profit cushion over interest right now.
What you should know
The case for and against HOWL
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -119.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.64x
P/B
2.90x
P/S
2.24x
EV/EBITDA
-1.24x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-24.7%
Operating margin
40.7%
Net margin
-164.8%
ROE
-119.9%
ROA
-27.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
2.91x
Quick ratio
2.80x
Total debt
$0.00
Total cash
$21.99M
Growth
How the business has been compounding
Revenue TTM
$21.00M
Revenue 5Y CAGR
—
EPS TTM
-0.73
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-30.15M
Free CF TTM
$-60.29M
FCF margin
-287.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—